Q2 Earnings Estimate for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Analysts at HC Wainwright dropped their Q2 2026 EPS estimates for shares of Genmab A/S in a report released on Tuesday, June 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.46 per share for the quarter, down from their prior estimate of $0.56. HC Wainwright currently has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.16 per share. HC Wainwright also issued estimates for Genmab A/S’s Q3 2026 earnings at $0.41 EPS, Q4 2026 earnings at $0.37 EPS and FY2026 earnings at $1.32 EPS.

Several other brokerages have also recently issued reports on GMAB. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Wolfe Research began coverage on Genmab A/S in a report on Friday, March 27th. They set an “outperform” rating and a $32.00 target price on the stock. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Wells Fargo & Company began coverage on shares of Genmab A/S in a research report on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective for the company. Finally, Weiss Ratings downgraded shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.93.

Genmab A/S Stock Performance

GMAB opened at $25.86 on Thursday. The company has a market capitalization of $16.12 billion, a price-to-earnings ratio of 19.59, a price-to-earnings-growth ratio of 1.54 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. Genmab A/S has a 1-year low of $20.23 and a 1-year high of $35.43. The business has a 50 day moving average price of $26.35 and a two-hundred day moving average price of $28.86.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently modified their holdings of GMAB. CIBC Private Wealth Group LLC increased its stake in Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 616 shares in the last quarter. Osaic Holdings Inc. lifted its stake in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Genmab A/S in the first quarter worth about $34,000. NewEdge Advisors LLC boosted its holdings in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after buying an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. increased its position in shares of Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after acquiring an additional 780 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.